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Abstract
Background: Although	used	for	decades	in	psoriasis,	access	to	phototherapy	is	be-
coming	increasingly	restricted.	Besides	patient	inconvenience,	this	is	in	large	part	to	
do	with	a	perception	of	“high	cost.”	We	previously	reported	a	comprehensive	analysis	
of	direct	and	indirect	phototherapy	treatment	cost.	However,	no	robust	data	exist	on	
the	actual	savings	associated	with	providing	phototherapy	in	the	treatment	pathway.
Objectives: To	quantify	the	cost	savings	achieved	by	phototherapy	by	delaying	alter-
native	treatments.
Methods: Costs	accruing	through	the	UK‐wide	established	treatment	pathway	with	
and	without	phototherapy	were	analysed.	Direct	and	indirectly	incurred	drug	treat-
ment	costs	were	calculated	using	drug	tariff,	laboratory	cost,	estate	rates	and	clinic	
review	costs.	To	enhance	reliability,	ranges	of	cost	scenarios	were	calculated	by	vary-
ing	parameters	such	as	drug	dosing.
Results: Medium	annual	cost	savings	per	patient	were	£2200	[range:	£1800‐£2900]	
for	NB‐UVB,	and	£3700	[range:	£2500‐£5300]	if	both	NB‐UVB	and	PUVA	courses	
were	administered,	respectively.	As	the	provider	treated	656	±	76	patients	per	year	
during	the	6‐year	observational	window,	this	amounted	to	savings	of	£Mio	2.4	[range:	
£Mio	1.6‐£Mio	3.4],	even	excluding	additional	non‐modelled	drug‐associated	costs	
(eg	 diagnostics,	 adverse	 event	management).	 Since	we	 only	 consider	 cost	 savings	
by	delay	of	drug	treatment	for	the	duration	of	phototherapy,	drug	price	reductions	
through	biosimilar	 introduction	only	have	a	small	effect.	We	provide	spreadsheets	
allowing	adaptation	cost	savings	projections	by	varying	input	variables.
Conclusions: Healthcare	 providers	may	 achieve	 significant	 cost	 savings	 by	 imple-
menting	and/or	widening	access	to	phototherapy.
K E Y W O R D S
health	economics,	NB‐UVB,	psoriasis,	treatment	pathways
1  | INTRODUC TION
Narrowband	 UVB	 (NB‐UVB)	 treatment	 is	 effective	 in	 psoriasis	
as	 shown	 in	numerous	clinical	 trials,1-5	 as	well	 as	 in	a	 recent	de-
tailed	real‐world	study	which	also	showed	that	NB‐UVB	achieved	
significant	reduction	in	the	use	of	steroid	creams.6	Although	widely	
used,	 the	 treatment	 is	 not	 uniformally	 available	 and,	 indeed,	 ac-
cess	appears	to	be	decreasing	in	the	United	States.7 The main lim-
itations	of	the	treatment	include	inconvenience	for	patients,	as	the	
treatment	requires	three	times	weekly	attendance,	a	perception	of	
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inferior	efficacy	(compared	to	biologics	treatment),	as	well	as	ex-
pense.	The	latter	is	reflected	in	treatment	guidelines,	such	as	the	
most	recently	published	British	Association	of	Dermatology	(BAD)	
guidelines	which	fail	to	even	include	NB‐UVB	in	the	biologic	drug	
treatment	pathway	(recommendation	R48).
Since	high‐quality	randomized	trials	are	almost	always	funded	by	
commercial	 sponsors,	 there	 is	 a	 relative	dearth	on	both	efficacy	as	
well	as	economics	data	for	phototherapy.	In	turn,	this	leads	to	under‐
representation	or	even	exclusion	 from	comparative	 treatment	anal-
yses	aiming	a	 synthesizing	clinical	 trial	data	 (eg	Ref.9,10).	To	address	
this	knowledge	gap,	we	recently	undertook	detailed	efficacy	analysis	
under	 real‐world	conditions	using	methodology	to	minimize	 report-
ing	and	selection	bias.12	Using	long‐term	comprehensive	data	from	a	
healthcare	provider	in	Scotland	(NHS	Tayside),	we	subsequently	pre-
sented	detailed	cost	figures,	showing	that	this	provider	had	incurred	
an	average	cost	of	£257	±	64	per	completed	course	over	the	course	of	
6	years.13	This	figure	included	both	direct	costs	(job	plan	allocations,	
support	staff),	as	well	as	an	exhaustive	 list	of	 indirect	cost	 (pension	
contributions,	 administration,	 estate,	 depreciation,	 etc),13	 and	 data	
were	obtained	from	four	independently	operated	sites,	thereby	mini-
mizing	random	effects	attributable	to	site‐specific	cost	efficiency.
In	the	present	study,	we	extend	this	analysis	towards	modelling	
the	 savings	 generated	 for	 the	healthcare	provider	 through	photo-
therapy	by	 the	 concomitant	delay	 and/or	 avoidance	of	 alternative	
treatments.	While	 large	majority	 of	 health	 economics	 analysis	 fo-
cussing	on	high‐cost	treatments	focusses	on	quality‐of‐life	aspects	
in	order	to	delineate	relative	cost‐effectiveness,	no	data	exist	to	as-
sess	the	cost	implications	of	inclusion	or	exclusion	of	phototherapy	
in	the	psoriasis	treatment	pathway.	The	present	study	addresses	this	
question.	By	limiting	modelling	to	the	provider	NHS	Tayside	as	case	
study,	we	are	able	 to	 reduce	uncertainty	associated	with	assump-
tions	since	we	draw	on	detailed	knowledge	of	direct	cost	 incurred	
by	phototherapy,13	local	treatment	pathways,	as	well	as	known	costs	
for	drug‐based	treatments.	Therefore,	various	parameters	determin-
ing	costing	scenarios	can	be	provided	with	a	high	degree	of	confi-
dence.	Despite	using	a	single	provider	for	modelling,	 the	model	as	
such	 is	directly	 transferable	to	any	other	health	economic	context	
by	adjusting	the	input	variables	to	reflect	local	practice,	respectively.
2  | METHODS
2.1 | Ethics statement
All	data	generated	 in	 this	study	were	obtained	 in	accordance	with	
the	 Declaration	 of	 Helsinki	 and	 in	 compliance	 with	 local	 govern-
ance	approval	regulations	(Caldicot	number	CSAppJF2101;	the	use	
of	 local	 Tayside	 phototherapy	 data	was	 approved	by	 the	National	
Managed	Clinical	Network	for	Phototherapy,	Photonet).
2.2 | NB‐UVB treatment data
Numbers	of	treated	patients	were	ascertained	from	the	PhotoSys	da-
tabase,	as	previously	described.6	The	cost	of	NB‐UVB	phototherapy	
has	 been	detailed	 recently.13	 The	 cost	 of	 one	 course	 of	 PUVA	 in-
curred	by	NHS	Tayside	has	been	calculated	as	follows:	The	number	of	
staff	hours,	estate	cost,	technician,	supervision,	admin	etc	detailed	in	
Reference13	(Tables	S2‐S6	therein)	is	identical	between	NB‐UVB	and	
PUVA,	respectively.	PUVA	incurs	extra	cost	owing	to	the	need	for	
medication	(8‐methoxypsoralen	tablets,	5‐methoxypsoralen	tablets,	
8‐MOP	bath	additive	and	8‐MOP	gel,	respectively),	as	well	as	differ-
ent	acquisition	cost	for	UVA	cabinets	instead	of	UVB	cabinets.	The	
difference	of	these	factors	has	previously	been	calculated	to	amount	
to	an	aggregate	3.3‐fold	higher	 cost	of	 a	PUVA	 treatment	 session	
compared	to	a	NB‐UVB	session14	(pp	85‐89	therein).	The	overall	cost	
of	an	entire	course	is	furthermore	directly	proportional	to	the	num-
ber	of	treatment	sessions	which	average	21.8	±	12.1	for	PUVA	and	
27.2	±	13.7	for	NB‐UVB	across	all	NHS	Tayside	sites,	respectively.	
Therefore,	the	cost	of	PUVA	=	[cost‐NB‐UVB]	×	3.3	×	[sessions‐PUVA/
sessionsNB‐UVB]	=	£257	×	3.3	×	0.8	=	£678.
2.3 | Cost factors in third‐line treatment
Laboratory	monitoring	cost	 incurred	by	 the	provider	was	supplied	
by	NHS	Tayside	Blood	Sciences	and	 is	detailed	 in	their	application	
to	various	drugs	 in	Figure	S1.	The	 frequency	of	 laboratory	 review	
was	set	at	four	times	annually	(low	and	medium)	or	six	times	annu-
ally	 (high).	 Cost	 for	 clinic	 review	 (Tayside	Dermatology	 outpatient	
appointment)	was	supplied	by	NHS	Tayside	Directorate	of	Finance/	
Operational	Unit	as	£167	(2018/19	rate),	which	is	also	in	line	with	the	
Scottish	average	of	£160.	The	figure	represents	full	economic	cost-
ing,	including	direct,	indirect	and	overhead	costs,	respectively.	The	
frequency	of	clinic	review	was	set	at	4	×	per	year,	assuming	(conserv-
atively)	steady	state	rather	than	the	review	frequency	encountered	
during	initial	treatment	induction.
2.4 | Non‐modelled cost elements
A	number	of	 cost	 emerging	with	drug	 treatment	were	not	mod-
elled	due	to	difficulty	in	establishing	precise	actual	frequencies	of	
episodes.	These	include	(a)	treatment	failures	occuring	at	less	than	
months	 after	 drug	 initiation,	 thereby	 incurring	 added	 compound	
expenditures	for	more	than	one	drug,	(b)	various/	additional	moni-
toring	required	in	a	subset	of	patients	only	(eg	tests	in	concurrent	
diabetes/	thyroid	disease/	haemochromatosis),	(c)	unscheduled	re-
view	and	additional	medication	in	response	to	adverse	effects	(eg	
significant	 nausea),	 (d)	 additional	 safety	 measures	 (vaccinations,	
chest	x‐ray	according	to	local	SOP).	In	addition,	not	modelled	were	
(e)	savings	achieved	through	phototherapy	replacing	non‐psoriasis	
conditions	(eg	urticaria,	atopic	dermatitis,	prurigo,	pruritus	in	the	
elderly).
2.5 | Drug costs
Costs	 for	 methotrexate,	 acitretin,	 ciclosporine	 were	 accessed	
through	 NHS	 drug	 tariff	 (http://www.drugt	ariff.nhsbsa.nhs.uk),	
respectively.	 Cost	 for	 dimethyl	 fumarate	was	 accessed	 at	 https	://
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www.sps.nhs.uk/medic	ines/dimet	hyl‐fumar	ate/.	 Cost	 for	 1st	 and	
2nd	line	Biologics	is	confidentially	negotiated	between	NHS	Tayside	
(and	many	other	healthcare	providers)	and	manufacturers,	 respec-
tively.	In	order	to	achieve	more	realistic	modelling,	therefore,	annual	
cost	of	£9000	and	£11	000,	 respectively,	was	set	 for	 the	medium	
cost	 scenario	 (see	Results)	 but	 can	be	 altered	 to	 reflect	 local	 cost	
figures.
3  | RESULTS
3.1 | The post‐phototherapy psoriasis treatment 
pathway
In	order	 to	delineate	the	cost	 for	 treatment	of	psoriasis	 that	 the	
provider	would	have	incurred	in	the	absence	of	phototherapy,	we	
used	 the	 treatment	pathway	currently	operative	 in	NHS	Tayside	
(Figure	1,	see	below	for	the	details)	which	is	similar	to	that	applied	
across	 the	UK	 and	 indeed	worldwide.15	NHS	Tayside	 local	 prac-
tice	includes	consideration	of	PUVA	in	patients	ahead	of	third‐line	
systemic	treatment.	For	that	reason,	we	performed	two	analyses,	
one	for	NB‐UVB	only	and	another	for	a	combination	of	NB‐UVB/
PUVA	into	a	single	phototherapy	treatment	 (and	cost)	block	 into	
the	model,	respectively	(Figure	1).	In	terms	of	specific	drugs,	their	
relative	prevalence	will	vary	regionally,	as	well	as	by	older	drugs	
being	superseded	by	new	drugs.	For	example,	in	the	present	case	
study,	use	of	apremilast,	 licensed	in	2015,	 is	 low	and	has	further	
decreased	 in	 NHS	 Tayside	 (Financial	 year	 2016/17:66	 prescrip-
tions/10,000	 population;	 financial	 year	 2017/18:54;	 data	 from	
HMUD	available	at	ISD	Scotland).	In	view	of	negligible	cost	impli-
cations	of	apremilast,	apremilast	has	therefore	been	omitted	from	
the	NHS	Tayside	case	study.
3.2 | Basic modelling parameters
The	 basic	 assumption	 is	 simply	 that	 completion	 of	 a	 course	 of	
NB‐UVB	 and	 PUVA,	 respectively,	 will	 delay	 the	 use	 of	 alterna-
tive	 treatment	 by	 12	months.	 This	 is	 an	 extremely	 conservative	
assumption	since	many	patients,	who	do	well	with	phototherapy,	
will	in	fact	undergo	repeat	treatment	for	years	before	moving	on	
to	drug	treatment.	In	addition,	we	have	previously	shown	that	NB‐
UVB	produces	good	clinical	outcomes	and	sustained	decrease	 in	
corticosteroid	treatment	for	at	least	12	months	after	treatment	in	
the	majority	of	patients.12	Therefore,	the	cost	difference	for	one	
course	of	NB‐UVB	will	be	the	delay	of	subsequent	treatments	by	
1 year.
3.3 | Modelling phototherapy‐based delay of 
drug treatment
For	any	given	financial	year,	therefore,	the	difference	in	cost	between	
the	current	practice	and	the	alternative	scenario	is	(Equation	1):
“Review”	 refers	 to	 a	 clinician	 review	 appointment	 which	 is	
scheduled	 between	 NB‐UVB	 and	 PUVA	 courses,	 respectively.	
P	=	probability	(termed	“likelihood”	in	Table	1)	of	drug	usage	given	
as	%	(representing	the	relative	discount	for	each	drug	in	the	treat-
ment	pathway)	in	Figure	1	(see	Table	1)	for	the	successive	pathway	
elements	 methotrexate,	 cyclosporine,	 dimethyl	 fumarate,	 1st	 line	
biologic,	2nd	 line	biologic,	respectively.	P	 incorporates	the	3%	dis-
count	rate	commonly	applied	in	cost‐effectiveness	modelling,16 re-
flected	 in	 successively	 lower	 values	 along	 the	 treatment	pathway.	
Importantly,	even	for	the	treatment	directly	replacing	phototherapy,	
P	was	set	to	a	conservative	value	of	66%	to	account	for	the	fact	that,	
in	practice,	a	number	of	patients	do	not	opt	for	any	alternative/addi-
tional	treatments	for	a	variety	of	reasons.
Any	 cost	 savings	 for	 each	 treatment	 step	 will	 not	 be	 realized	
instantaneously,	but	at	various	subsequent	time	points,	wherefore	
Equation	1	 represents	 cumulative	 savings	 (effects	of	 inflation	 and	
varying	interest	rates	are	ignored).	The	cost	for	each	treatment	step	
was	set	for	a	12‐month	treatment	window,	which	is	also	conserva-
tive,	 since	most	 treatments	 are	 dispensed	 for	 longer	 (eg	we	 have	
previously	reported	median	treatment	duration	of	methotrexate	as	
significantly	 longer	 than	 that17).	 This	 setting	 allows	 calculation	 of	
(1)
Cost difference=
[
Cost
(
NB − UVB
)
+Cost
(
PUVA
)
+Review
]
×1.2−2×Σ
(
PDrug×costDrug
)
F I G U R E  1  Model	used	to	calculate	cost	of	treatment	for	psoriasis	incurred	by	NHS	Tayside	in	the	absence	of	phototherapy.	Numbers	
printed	in	white	denote	percentages	of	original	“UVB/PUVA	failed”	patient	pool.	Numbers	in	black	print	denote	fraction	of	the	population‐
pool	progressing	from	one	to	the	next	step	in	the	treatment	pathway,	respectively.	Dashed	arrows	denote	alternate	treatment	pathways	not	
included	in	the	overall	cost	scenario.	“DMF”—Dimethyl	fumarate	(brand	name	currently	marketed	in	the	UK	“Skilarence”)
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cost	savings	incurred	by	delay	of	the	subsequent	treatment	step	by	
one	financial	year.
3.4 | Actual versus theoretical phototherapy 
treatment cost
In	clinical	practice,	a	subset	of	patients	may	in	fact	undergo	sub-
sequent	courses	of	either	UVB	or	PUVA	in	less	than	12	months,	
thereby	 increasing	the	cost	 incurred.	For	NHS	Tayside,	this	fac-
tor	can	be	readily	quantified.	Thus,	across	the	previous	six	finan-
cial	years	an	average	of	656	±	76	patients	underwent	788	±	98	
courses	 of	 phototherapy	 (either	UVB	 or	 PUVA).	 Therefore,	 the	
actual	 cost	 incurred	 for	 the	 provider	 NHS	 Tayside	 has	 in	 fact	
been	 788/656	 =	 1.20	 times	 the	 cost	 of	 one	 treatment	 course,	
which	 has	 accordingly	 incorporated	 as	 correction	 factor	 into	
Equation	1.
3.5 | Actual‐ versus Qaly‐based costs
For	high‐cost	drug	treatment,	most	healthcare	providers	require	ob-
jective	outcome	measures,	most	commonly	the	so‐called	PASI	or	IGA	
indices.	A	drop	below	PASI50	(that	is:	50%	worsening	from	baseline)	
is	then	used	to	trigger	moving	to	the	next	treatment	in	the	pathway.	
These	scores	are	not	commonly	recorded	for	traditional	treatments	
including	 phototherapy,	 and	 we	 therefore	 have	 refrained	 from	 in-
corporating	assumptions.	However,	 it	 is	worth	noting	that	we	have	
previously	 shown	 that	 the	 degree	 of	 disease	 control	 by	 NB‐UVB	
is	 comparable	 to	 that	 achieved	 by	 methotrexate	 under	 real‐world	
conditions,6,17,18	and	that	response	rates	are	similar	to	clinical	study	
results	reported	for	apremilast,	DMF	and	etanercept.19-21	Although	
the	 subjectively	 experienced	 degree	 of	 disease	 control,	 that	 is	 the	
“health	benefit,”	 is	 likely	higher	using	a	biologic	drug,	 it	 is	therefore	
reasonable	to	assume	that	any	given	patient	will	not	continue	pho-
totherapy	in	the	absence	of	a	subjective	benefit	justifying	treatment	
attendance.
3.6 | Modelling of NB‐UVB‐only cost differences
Since	many	 providers	may	 only	 offer	NB‐UVB	 treatment,	 it	 is	 in-
structive	to	calculate	hypothetical	cost	differences	associated	only	
with	NB‐UVB.	 In	 this	 alternative	 scenario,	 the	delay	 in	 the	use	of	
third‐line	treatment	is	shortened	from	24	to	12	months	and	no	CR	
review	is	required	prior	to	PUVA,	yielding	Equation	2:
3.7 | Modelling the likelihood of 
alternative treatments
For	 the	 calculation	of	 cost	 savings	by	NHS	Tayside,	 the	most	 fre-
quently	used	dose	ranges	are	summarized	in	Table	2.	The	likelihood	
for	alternative	treatments	(Table	1)	was	set	based	on	the	economical	
impact	 at	 the	 time	 of	 initiation	 of	NB‐UVB.	 Thus,	 biologics	 treat-
ments,	for	example,	although	expensive,	do	not	account	for	a	large	
proportion	of	cost	savings	in	this	particular	scenario,	since	their	posi-
tion	in	the	treatment	pathway	is	further	removed	in	time.	However,	
all	parameters,	including	drugs,	assumed	treatment	duration,	dosing,	
numbers	of	patients	 treated	can	be	adapted	and	altered	to	reflect	
practice	operative	in	other	healthcare	providers	(Figure	S1).
3.8 | Phototherapy‐associated cost savings
The	results	pertinent	for	NHS	Tayside	are	summarized	in	Table	3	with	
exact	data	sources	provided	in	Figures	S1	and	S2.	The	data	indicate	
(2)Cost difference=
[
Cost
(
NB − UVB
)]
×1.2−Σ
(
PDrug×costDrug
)
 
Likelihood of use (%)b
Cost displaced per patient by 
UVB (£)c
Low Medium Highd Low Medium High
Methotrexate 50 66 70 349 461 492
Acitretin 30 40 44 221 303 337
Ciclosporine 5 10 15 38 77 141
Fumarate 18 22 25 831 916 1,138
1st	biologic 3 5 7 292 487 682
2nd	biologic 1 2 4 117 234 469
aThe	table	details	costs	(given	in	£)	arising	as	a	result	of	the	drug	tarif‐based	or	listed	drug	prices	
(see	Figure	S1)	for	each	drug	at	the	assumed	annual	dose	requirement	detailed	in	Figures	S1,	F2.	
bThe	costs	shown	in	the	table	only	detail	costs	accruing	during	the	year	of	treatment	displaced	
by	phototherapy.	Therefore,	the	theoretical	treatment	cost,	for	example	for	a	first	biologic,	only	
occurs	with	a	3%‐7%	likelihood,	respectively.	This	likelihood	(“discount”)	has	been	applied	to	the	
annual	treatment	cost	to	yield	the	net	cost	displaced	by	phototherapy	treatment.	
cThe	cost	accruing	for	each	drug	includes	clinic	review	(4	per	year	for	“low/medium,”	6	per	year	for	
“high”)	as	well	as	laboratory	cost	specific	for	each	drug	(see	Figure	S1).	
dThe	likelihood	of	use	and	selection	of	drugs	(eg	a	medium	scenario	of	two‐thirds	of	patients	not	
offered	phototherapy,	to	be	offered	methotrexate)	is	based	on	known	figures	in	NHS	Tayside	but	
can	be	adapted	to	any	other	economical	context.	
TA B L E  1  Drug‐associated	costs	
displaced	by	phototherapya
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that	the	provider	would	have	incurred	significant	additional	cost	in	
the	 absence	 of	 either	 combined	 phototherapy	 (NB‐UVB	 +	 PUVA)	
or	NB‐UVB	only.	The	numbers	in	the	“medium”	scenario	reflect	ac-
tual	savings	most	closely	based	on	local	treatment	patterns	(includ-
ing	both	 retention	 time	and	dosing	 ranges)	and	costings,	 including	
staff‐related	factors.	Even	when	assuming	a	50%	discounted	cost	for	
clinic	review	appointments	(ie	allowing	that	the	actual	cost	incurred	
is	only	half	to	that	stated	by	the	provider),	savings	remain	significant	
(Table	3,	bottom	two	lines).	Furthermore,	the	data	shown	represent	
a	conservative	estimate	as	follows:	First,	a	number	of	yet	additional	
cost	factors	associated	with	drug	treatment	were	not	added	in	order	
to	 minimize	 assumption	 based	 uncertainty	 (see	Methods,	 section	
“non‐modelled	cost	elements”).	Second,	a	significant	fraction	of	pa-
tients	on	NB‐UVB	achieves	retention	times	for	several	years	before	
(if	ever)	requiring	third‐line	drug	treatment,	adding	further	savings.	
Importantly,	due	to	the	discounting	incorporated,	any	change	in	pric-
ing	in	biologics	(eg	biosimilar	replacement)	would	only	have	a	minor	
impact	on	the	savings.
4  | DISCUSSION
4.1 | Modelling cost savings in pathway‐organized 
medical care
When	assessing	cost‐effectiveness,	models	are	commonly	applied	
to	account	for	variable	health	benefits	afforded	by	alternative	or	
sequential	health	interventions.	For	the	chronic	condition	psoria-
sis,	for	example,	Health	Technology	Appraisals	by	the	UK	econom-
ics	watch	dog	NICE	commonly	assume	greater	health	benefit	for	
biologic	drugs,	impacting	on	a	“value	for	money”	type	of	approach	
for	 these	 high‐cost	 drugs.	 By	 contrast,	we	 here	 exploit	 detailed	
knowledge	 of	 the	 response	 of	 psoriasis	 to	 phototherapy	 as	well	
as	comparator	 treatments6,17‐21	 in	order	 to	simplify	modelling	by	
aligning	 it	with	clinical	practice:	regardless	of	a	specific	PASI	 im-
provement,	 a	 given	 patient	 is	 likely	 to	 progress	 along	 the	 treat-
ment	pathway	if	a	subjectively	“insufficient”	experienced	level	of	
disease	control	 is	encountered,	as	shown	previously	 in	detail	 for	
methotrexate.17	We	therefore	also	disregard	potential	savings	by	
reduced	requirement	for	steroid	cream	treatment,	which	we	have	
previously	shown	for	NB‐UVB,6	as	this	specific	is	likely	be	compa-
rable	for	any	effective	intervention.	Because	of	conservative	dis-
counting,	the	overall	contribution	of	both	1st	and	2nd	line	biologic	
combined	only	amounts	to	30%	of	the	overall	savings	(Supporting	
Excel	 files	1,	 2)	 obviating	 any	 further	 need	 to	 adjust	 for	 greater	
health	benefit.	Importantly,	discounting	means	that	even	changing	
TA B L E  2  Drug	doses	and	fixed	drug	prices	used	to	calculate	
cost	savings	associated	with	displacement	of	drug	treatment	by	
phototherapy	(UVB/PUVA)a
Treatment scenariob,g Lowb,c Medium High
Methotrexate 12.5	mg 15	mg 20	mg
Acitretin 10	mg 25	mg 30	mg
Ciclosporine 200	mgf 200	mg 300	mg
Dimethyl	fumarate 4	tabsd 4.5	tabs 5	tabs
1st	line	biologic £7000e £9000 £9000
2nd	line	biologic £9000e £11	000 £11	000
aFor	details	see	text;	the	“medium	savings”	scenario	is	represented	in	
Figure	1.	Treatment	likelihoods	and	dosing	are	modelled	according	to	
NHS	Tayside	local	practice.	
bScenarios	calculated	using	Equation	1	and	2,	respectively,	see	Figure	
S1.	
cDose	is	daily	except	for	methotrexate	(weekly)	and	biologics	(annual	
flat	cost	rate).	In	accordance	with	common	usage,	ciclosporine	dosage	
is	assumed	6	mo	for	medium/high	scenarios	and	3	mo	for	low	scenario,	
respectively.	
dLong‐term	average	daily	steady‐state	dosing;	initial	dose	induction	is	
not	modelled.	
eFor	most	providers,	including	NHS	Tayside,	confidential	flat	annual	
rates	are	negotiated	with	suppliers.	Cost	figures	shown	represent	
annual	cost	likely	incurred	per	patient.	
fLow	scenario	ignores	initial	high‐frequency	laboratory	for	up‐dosing.	
gLow	and	medium	scenarios	assume	steady‐state	review;	high	scenario	
incorporates	higher	frequency	due	to	adverse	effects	and/or	need	to	
change	treatment.	
  
Medium Range
Cost (£) Low High
Per	Patient NB‐UVB	+	PUVA 3727 2469 5284
For	all	patientsb Mio	2.44 Mio	1.62 Mio	3.47
Per	Patient NB‐UVB	onlyc 2169 1849 2948
For	all	patients Mio	1.42 Mio 1.21 Mio	1.93
Per	Patient NB‐UVB	discountedd 1685 1479 2397
For	all	patients Mio 1.11 0.97 1.57
aData	shown	represent	net	savings	hypothetically	achieved	by	NHS	Tayside,	using	input	variables	
detailed	in	Table	2	and	Equation	1	(for	details	see	Supporting	Excel	file	1).	
bData	shown	for	n	=	656	±	76	of	psoriasis	patient	treated	on	average	across	NHS	Tayside	during	
the	previous	three	financial	years.	
cFor	NB‐UVB	only,	the	cost	of	PUVA	was	omitted	and	the	delay	in	third‐line	treatment	was	short-
ened	from	24	to	12	mo.	Details	are	shown	in	Supporting	Excel	file	2.	
dAssuming	a	fifty	per	cent	discounted	cost	of	Clinician	Review	from	fully	economical	cost.	
TA B L E  3  Cost	savings	associated	with	
delay/avoidance	of	third‐line	treatment	by	
NHS	Tayside.a
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the	drug	cost	 from	£9000	 to	£3000,	 as	 currently	 the	case	after	
biosimilar	introduction,	only	has	a	minor	impact	on	the	overall	cost	
savings.	Since	the	model	shown	in	Figure	1	in	fact	represents	the	
actual,	 not	 hypothetical,	 post‐phototherapy	 treatment	 pathway,	
the	cost	figures	summarized	in	Table	3	represent	a	rather	realistic	
model	scenario.
4.2 | Limitations
Our	 study	has	 two	main	 limitations.	First,	we	do	not	 consider	pa-
tient‐incurred	cost,	in	particular	absence	from	work	place	enforced	
by	treatment	attendance.	In	this	regard,	it	should	be	noted	that	many	
providers	 attempt	 to	minimize	 such	 cost	 by	 offering	 out‐of‐hours	
access,	home	treatment,	or	hospital‐based	self‐treatment	NB‐UVB	
units,22,23	requiring	more	differentiated	modelling	of	this	factor.	One	
intriguing	aspect	emerging	from	the	current	data,	however,	 is	 that	
the	potential	savings	for	the	provider	are	likely	substantial	enough	
to	warrant	incentivizing	patients	to	utilize	phototherapy	by	integra-
tion	of	fractional	savings	achieved	into	health	plan	contributions.	A	
second	major	limitation	is	that	quality‐of‐life	cost	implications	were	
not	modelled	due	to	lack	of	data.
In	 terms	of	 the	dominant	cost	 factor,	 staff	 time,	we	previously	
detailed	direct	and	indirect	staff	hours	required	to	supply	NB‐UVB,	
facilitating	more	 predictive	model	 building.6	 The	 key	 factor,	 iden-
tified	 therein,	 driving	 cost‐effectiveness	was	 low	 actual	 hands‐on	
time,	 requiring	 only	 0.45	±	 0.14	 staff	 hours	 (including	 both	 direct	
and	support	staff	roles)	per	completed	NB‐UVB	course.	The	obvious	
fundamental	 difference	 to	 drug‐based	 treatment	 is	 that	 costs	 de-
crease	with	increase	of	patients	treated,	which	is	the	direct	opposite	
of	pharmacotherapy,	as	recently	reported	for	Spain.24
The	considerable	cost	savings	potential	of	phototherapy	demon-
strated	here	is	of	particular	relevance	given	huge	financial	pressures	
placed	on	providers.	In	that	regard,	it	is	notable	that	NB‐UVB	is	ap-
propriate	as	 long‐term	 intercurrent	 treatment	and	can	be	adminis-
tered	 in	clinical	 settings	often	 limiting	 for	drug	 treatment,	 such	as	
late	pregnancy,	anticipated	family	planning,	or	hepatic	dysfunction.	
Although	we	have	 shown	 that	even	 for	 treatment	 sites	with	 small	
patient	 throughput	 (around	100	courses	per	year)	 cumulative	cost	
are	similar	to	larger	sites,6	the	cost	savings	potential	is	of	particular	
relevance	to	large	providers.
4.3 | NB‐UVB and phototherapy in psoriasis 
treatment pathways
The	 cost	 savings	 potential	 in	 conjunction	 with	 established	 effi-
cacy	begs	the	question	as	to	why	this	treatment	is	not	more	widely	
made	 available.	 For	 example,	 the	 current	 British	 Association	 of	
Dermatologist	(BAD)	guidelines	do	not	even	consider	NB‐UVB	on	the	
pathway	to	Biologics	treatment.8	Similarly,	many	guidelines	consider	
NB‐UVB	as	a	treatment	option	but	not	one	which	should	be	actively	
encouraged.	 The	 current	 guidelines	 of	 the	 US	 American	 Academy	
of	Dermatology	also	do	not	even	suggest	that	NB‐UVB	ought	to	be	
actively	considered	before	moving	to	systemic	treatments.	Likewise,	
the	National	Psoriasis	Foundation	opposes	any	effort	to	apply	cost‐
effective	treatments	ahead	of	more	expensive	alternatives	(which	the	
NPF	terms	“step	therapy”),	lobbying	actively	for	legislation	to	ban	this	
approach.25	In	some	cases,	safety	concerns	are	cited	even	in	the	ab-
sence	of	data.	Specifically,	in	terms	of	safety,	available	studies	have	
not	identified	any	skin	cancer	risks	for	NB‐UVB.26‐30	In	this	regard,	we	
are	currently	analysing	data	on	>50	000	individual	patients	treated	
with	NB‐UVB	throughout	Scotland	since	the	mid‐1980s.	Preliminary	
results	do	not	indicate	increased	incidence	in	cancer	levels	in	this	co-
hort	(RD,	manuscript	in	preparation).	We	anticipate	that	the	data	pre-
sented	 here	will	 encourage	 providers	 to	 re‐evaluate	 phototherapy,	
and	in	particular	NB‐UVB,	within	psoriasis	treatment	pathways.
Finally,	phototherapy	is	also	used	for	many	other	diseases,	with	
good	 controlled	 study	 evidence	 supporting	 efficacy	 in	 eczema	
and	 chronic	 urticaria,31‐33	 offering	 further	 potential	 econonomical	
synergy.
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